CI
BMRN icon

Cordant Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cordant Inc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$916 Hold
16
– – ﹤0.01% 157
2026
Q1 		$904 Hold
16
– – ﹤0.01% 71
2025
Q4 		$951 Buy
+16
New +$871 ﹤0.01% 66
2022
Q2 		– Sell
-25
Closed -$2K – 216
2022
Q1 		$2K Buy
+25
New +$2.09K ﹤0.01% 591

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Cordant Inc's BMRN Position: Q2 2026 in Review

Cordant Inc held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 16 shares worth $916. The position accounts for ﹤0.01% of the portfolio, ranked #157.

Cordant Inc first reported a position in BMRN in Q1 2022 and has held it in 4 quarters since. The position peaked at $2K in Q1 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Cordant Inc held 16 shares of BioMarin Pharmaceuticals worth $916 as of Q2 2026.
  • Cordant Inc left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #157 holding.
  • Cordant Inc first reported a position in BioMarin Pharmaceuticals in Q1 2022 and has held it in 4 quarters since.
  • Cordant Inc's BioMarin Pharmaceuticals position peaked at $2K in Q1 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.